Kazano Alternatives Compared
| Kazano (alogliptin / metformin) | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|
|---|
| Kazano (alogliptin / metformin) | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Diabetes - Type 2. Kazano may also be used for purposes not listed in this medication guide. |
Prescription only
Ozempic lowers blood sugar levels by mimicking the effects of GLP-1, a naturally occurring hormone that stimulates insulin secretion and lowers glucagon secretion from the liver. It is... View more |
Prescription only
Prescribed for Weight Loss (Obesity/Overweight), Diabetes - Type 2. Mounjaro may also be used for purposes not listed in this medication guide. |
Related suggestions Diabetes, Type 2
|
|||||||||||||||||||||||
| More about Kazano (alogliptin / metformin) | More about Ozempic (semaglutide) | More about Mounjaro (tirzepatide) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Kazano has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Ozempic has an average rating of 6.6 out of 10 from a total of 1364 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 24% reported a negative effect. |
Mounjaro has an average rating of 8.6 out of 10 from a total of 1078 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 7% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Kazano prices |
View all Ozempic prices |
View all Mounjaro prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other semaglutide brands include: Rybelsus, Wegovy | Other tirzepatide brands include: Zepbound | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
21 hours |
168 hours |
120 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 373 drugs are known to interact with Kazano:
|
A total of 266 drugs are known to interact with Ozempic:
|
A total of 411 drugs are known to interact with Mounjaro:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
January 25, 2013 |
N/A |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.